2022 innovations in dermatology domain

Axel De Greef, M.D., Marie Baeck, M.D., Ph.D. Published in the journal : February 2023 Category : Dermatology

Summary :

The emergence of Janus kinase inhibitors (JAKi) in the medical dermatology arsenal has enabled a considerable advancement in the management of several inflammatory skin diseases, such as atopic dermatitis or autoimmune diseases like alopecia areata or vitiligo. JAKi’s broad action profile in terms of cytokine blockade, which has been associated with beneficial therapeutic effects, nonetheless requires a certain degree of precaution with respect to the safety profile of this drug class. This article sought to review the latest safety data on JAKi. As shown herein, it is essential to distinguish the risk in keeping with the populations treated and the pathologies targeted by these molecules. Yet, caution is still required in elderly patients, in those with cardiovascular risk factors including active or past smoking, as well as those with a previous cancer.

Key Words

Atopic dermatitis, alopecia areata, vitiligo, inflammatory diseases, Janus kinase inhibitors, safety